Oncolytics Biotech Ownership
| ONCY Stock | USD 0.63 0.01 1.61% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 76.1 M | Current Value 76.1 M | Avarage Shares Outstanding 18 M | Quarterly Volatility 22.3 M |
Oncolytics |
Oncolytics Stock Ownership Analysis
The company recorded a loss per share of 0.29. Oncolytics Biotech last dividend was issued on the 25th of May 2018. The entity had 10:95 split on the 25th of May 2018. Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada. Oncolytics Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 26 people. To find out more about Oncolytics Biotech contact Dr MBA at 403 670 7377 or learn more at https://www.oncolyticsbiotech.com.Besides selling stocks to institutional investors, Oncolytics Biotech also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Oncolytics Biotech's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Oncolytics Biotech's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Oncolytics Biotech Quarterly Liabilities And Stockholders Equity |
|
About 4.0% of Oncolytics Biotech are currently held by insiders. Unlike Oncolytics Biotech's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Oncolytics Biotech's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Oncolytics Biotech's insider trades
Oncolytics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Oncolytics Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oncolytics Biotech backward and forwards among themselves. Oncolytics Biotech's institutional investor refers to the entity that pools money to purchase Oncolytics Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Seacrest Wealth Management, Llc | 2024-12-31 | 26 K | Brave Asset Management Inc | 2024-12-31 | 25 K | Newman Dignan & Sheerar Inc | 2024-12-31 | 22.9 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 22.9 K | Ubs Group Ag | 2024-12-31 | 20.9 K | Financial Advisory Corp /ut/ /adv | 2024-12-31 | 20.6 K | Head & Associates, Llc | 2024-12-31 | 19.8 K | Lpl Financial Corp | 2024-12-31 | 16 K | Federation Des Caisses Desjardins Du Quebec | 2024-12-31 | 15.8 K | Seeds Investor Llc | 2024-12-31 | 189.9 K | International Assets Investment Management, Llc | 2024-09-30 | 174.3 K |
Oncolytics Biotech Outstanding Bonds
Oncolytics Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Oncolytics Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Oncolytics bonds can be classified according to their maturity, which is the date when Oncolytics Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.